The aim of this work is to develop and validate a simple, accurate, precise, stability-indicating and economic analysis protocol for EGCG. The applicability of LLE and SPE for sample clean-up and enrichment of target analyte is investigated. Monitoring the integrity of EGCG in tablet dosage form is carried out, after applying stress conditions commonly required for registration of pharmaceutical products. A possible approach to obviate the need for a reference standard of the studied analyte is suggested. The use of an internal standard (IS) and integration of advanced mass spectrometry into the analysis protocol is explored. The proposed protocol is used to evaluate the stability of a commercially available GT tablet formulation under accelerated stability conditions.